Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transmural healing with ustekinumab in moderate to severe Crohn's disease (China, EUS assessment)
ChiCTR2300078772Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in Crohn's disease, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: C-reactive protein, Fecal calprotectin and 4 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2300078772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078772.